Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application

Premium

Alnylam Pharmaceuticals and Isis Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a US patent application covering chemically modified RNA-containing therapeutics.

The application, No. 20020165189, is entitled, "Oligoribonucleotides and Ribonucleases for Cleaving RNA," and specifically claims "oligoribonucleotides and oligoribonucleosides … [with] subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase," according to its abstract.

"The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics," the abstract adds.

The patent is assigned to Isis, and has been licensed to Alnylam.